pdf   xlsx method abbreviations

hepatocell cancer (HCC), nivolumab based treatment , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.85 [0.71, 1.01]< 10%1 study (1/-)96.6 %NAnot evaluable crucial-
progression or deaths (PFS) 0.93 [0.79, 1.10]< 10%1 study (1/-)80.5 %NAnot evaluable important-
objective responses (ORR) 2.42 [1.48, 3.94]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

STRAE (grade 3-4) 0.30 [0.22, 0.41]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 0.53 [0.28, 1.00]< 10%1 study (1/-)97.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.